Researchers from Ghent University Describe Findings in Pharmaceutical Research and Biopharmaceuticals (Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs)
By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Drugs and Therapies have been presented. According to news originating from Ghent, Belgium, by NewsRx correspondents, research stated, "The aim of the study is to increase the bioavailability of itraconazole (ITRA) using nanosized cocrystals prepared via wet milling of ITRA in combination with dicarboxylic acids. Wet milling was used in order to create a nanosuspension of ITRA in combination with dicarboxylic acids."
Our news journalists obtained a quote from the research from Ghent University, "After spray-drying and bead layering, solid state was characterized by MDSC, XRD, Raman and FT-IR. The release profiles and bioavailability of the nanococrystalline suspension, the spray-dried and bead layered formulation were evaluated. A monodisperse nanosuspension (549 +/- 51 nm) of ITRA was developed using adipic acid and Tween ® 80. Solid state characterization indicated the formation of nanococrystals by hydrogen bounds between the triazole group of ITRA and the carboxyl group of adipic acid. A bioavailability study was performed in dogs. The faster drug release from the nanocrystal-based formulation was reflected in the in vivo results since T-max of the formulations was obtained 3 h after administration, while T-max of the reference formulation was observed only 6 h after administration. This fast release of ITRA was obtained by a dual concept: manufacturing of nanosized cocrystals of ITRA and adipic acid via wet milling."
According to the news editors, the research concluded: "Formation of stable nanosized cocrystals via this approach seems a good alternative for amorphous systems to increase the solubility and obtain a fast drug release of BCS class II drugs."
For more information on this research see: Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs. European Journal of Pharmaceutics and Biopharmaceutics, 2014;87(1):107-113. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)
The news correspondents report that additional information may be obtained from L. De Smet, University of Ghent, Lab Med Biochem & Clin Anal, B-9000 Ghent, Belgium. Additional authors for this research include L. Saerens, T. De Beer, R. Carleer, P. Adriaensens, J. Van Bocxlaer, C. Vervaet and J.P. Remon (see also Drugs and Therapies).
Keywords for this news article include: Ghent, Belgium, Europe, Drugs and Therapies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC